Chlorpheniramine
- Generic Name
- Chlorpheniramine
- Brand Names
- Aller-chlor, Allerest PE, Children's Nyquil Cold and Cough, Codar Ar, Coricidin Hbp Cold & Flu, Coricidin Hbp Cough and Cold, Dimetapp Long Acting Cough Plus Cold, Robitussin Pediatric Cough & Cold LA, Scot-tussin Sugar Free DM, Sudogest, Tussicaps, Tussionex, Tuxarin, Tuzistra, Wal-finate
- Drug Type
- Small Molecule
- Chemical Formula
- C16H19ClN2
- CAS Number
- 132-22-9
- Unique Ingredient Identifier
- 3U6IO1965U
- Background
A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine.
- Indication
For the treatment of rhinitis, urticaria, allergy, common cold, asthma and hay fever.
- Associated Conditions
- Allergic Conjunctivitis (AC), Allergic Contact Dermatitis, Allergic Reaction, Allergic Rhinitis (AR), Allergic cough, Allergies caused by Serum, Allergy to Tree Pollen, Allergy to vaccine, Angioneurotic Edema, Asthma, Bronchial Asthma, Bronchitis, Common Cold, Conjunctival congestion, Conjunctivitis, Cough, Cough caused by Common Cold, Coughing caused by Flu caused by Influenza, Drug Allergy, Epiphora, Eye allergy, Fever, Flu caused by Influenza, Food Allergy, Headache, Headache caused by Allergies, House Dust Mite Allergy, Itching of the nose, Itching of the throat, Migraine, Nasal Congestion, Nasal Congestion caused by Common Cold, Productive cough, Pruritus, Rash, Rhinorrhoea, Seasonal Allergic Conjunctivitis, Sinus Congestion, Sinusitis, Sneezing, Transfusion Reactions, Upper Respiratory Tract Infection, Upper respiratory tract congestion, Upper respiratory tract hypersensitivity reaction, site unspecified, Urticaria, Vasomotor Rhinitis, Acute Rhinitis, Allergic purpura, Conjunctival hyperemia, Dry cough, Excess mucus or phlegm, Itchy throat, Mild bacterial upper respiratory tract infections, Ocular hyperemia, Throat inflammation, Upper respiratory symptoms, Watery itchy eyes
- Associated Therapies
- Airway secretion clearance therapy
Evaluating efficacy and safety of ocrelizumab biosimilar (Xacrel) compared to the originator
A randomized, double-blind, phase III clinical trial (Aug 2019–Oct 2021) in Iran compared Xacrel (300 mg, then 600 mg every 24 weeks) to Ocrevus (same regimen) in MS patients. Primary outcome was ARR reduction equivalence at week 48. Secondary outcomes included disability progression, relapse-free patients, MRI lesion changes, and safety assessments. The study adhered to ethical and regulatory standards.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath